BMO Capital Upgrades Beam Therapeutics: Here's What You Need To Know

BMO Capital upgraded its rating of Beam Therapeutics BEAM to Outperform with a price target of $66.00, changing its price target from $61.00 to $66.00.

Shares of Beam Therapeutics are trading up 1.33% over the last 24 hours, at $40.63 per share.

A move to $66.00 would account for a 62.42% increase from the current share price.

About Beam Therapeutics

Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing.

About Analyst Ratings

Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.

Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.

If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along with analyst success scores in Benzinga Pro.

This article was generated by Benzinga's automated content engine and reviewed by an editor.